My understanding is that GALT is supplying the drug only for the melanoma trials. If those trials follow the pre clinical findings I'll bet that Merck will be putting in a big bid to buy.
It's fairly quick trial time too for keytruda and yervoy are already approved and in use. What would our value be if GR-MD-02 were approved as an additive therapy for most types of cancers?
News 
Market Data 
Discover 
AI
